Ignite Creation Date:
2025-12-24 @ 9:47 PM
Ignite Modification Date:
2025-12-25 @ 7:26 PM
Study NCT ID:
NCT02551432
Status:
COMPLETED
Last Update Posted:
2020-02-10
First Post:
2015-07-07
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Sponsor:
Seoul National University Hospital
Organization:
Study Overview
Official Title:
Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MISP-MK3475
Brief Summary:
Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.
Detailed Description:
Open, uncontrolled, multi-center, phase II study.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: